William Liang Hwang, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Pancreatic Ductal | 5 | 2023 | 1634 | 1.040 |
Why?
|
| Nerve Tissue | 1 | 2021 | 79 | 0.760 |
Why?
|
| Lipid Bilayers | 5 | 2009 | 381 | 0.740 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2018 | 934 | 0.730 |
Why?
|
| Pancreatic Neoplasms | 6 | 2023 | 5256 | 0.710 |
Why?
|
| Neurosciences | 1 | 2022 | 348 | 0.590 |
Why?
|
| Meningioma | 4 | 2019 | 1209 | 0.540 |
Why?
|
| Neoplasms | 7 | 2022 | 21683 | 0.510 |
Why?
|
| Nucleosomes | 3 | 2016 | 494 | 0.500 |
Why?
|
| Prognosis | 17 | 2022 | 29063 | 0.460 |
Why?
|
| Meningeal Neoplasms | 3 | 2019 | 1241 | 0.450 |
Why?
|
| DNA, Neoplasm | 1 | 2018 | 1758 | 0.440 |
Why?
|
| Prostatectomy | 2 | 2018 | 1890 | 0.440 |
Why?
|
| Esophagus | 1 | 2018 | 1019 | 0.420 |
Why?
|
| Postoperative Care | 1 | 2018 | 1486 | 0.400 |
Why?
|
| Neuroblastoma | 1 | 2019 | 1226 | 0.390 |
Why?
|
| DNA Copy Number Variations | 2 | 2022 | 1941 | 0.380 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2020 | 1770 | 0.370 |
Why?
|
| Esophageal Neoplasms | 1 | 2018 | 1583 | 0.320 |
Why?
|
| Alkanes | 1 | 2008 | 45 | 0.320 |
Why?
|
| Gene Expression Profiling | 2 | 2022 | 9438 | 0.320 |
Why?
|
| Computing Methodologies | 1 | 2007 | 17 | 0.310 |
Why?
|
| Oils | 1 | 2007 | 63 | 0.300 |
Why?
|
| Immunotherapy | 2 | 2021 | 4445 | 0.280 |
Why?
|
| Water | 3 | 2008 | 1395 | 0.260 |
Why?
|
| Prostatic Neoplasms | 2 | 2018 | 11124 | 0.260 |
Why?
|
| Histones | 2 | 2016 | 2599 | 0.250 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2019 | 477 | 0.230 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2022 | 5221 | 0.220 |
Why?
|
| Papillomavirus Infections | 3 | 2020 | 1587 | 0.220 |
Why?
|
| Lung Neoplasms | 4 | 2022 | 13102 | 0.220 |
Why?
|
| Papillomaviridae | 2 | 2019 | 1119 | 0.220 |
Why?
|
| Salvage Therapy | 3 | 2018 | 1275 | 0.220 |
Why?
|
| Radiation Injuries | 2 | 2020 | 1180 | 0.210 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3133 | 0.210 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3240 | 0.210 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2021 | 49 | 0.200 |
Why?
|
| Nervous System Physiological Phenomena | 1 | 2022 | 117 | 0.200 |
Why?
|
| Combined Modality Therapy | 6 | 2019 | 8642 | 0.200 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 147 | 0.190 |
Why?
|
| Lipids | 3 | 2008 | 3305 | 0.180 |
Why?
|
| Disease-Free Survival | 4 | 2019 | 6895 | 0.180 |
Why?
|
| Pandemics | 1 | 2020 | 8388 | 0.180 |
Why?
|
| Adenosine Triphosphatases | 2 | 2014 | 839 | 0.170 |
Why?
|
| Neoplasm Metastasis | 3 | 2019 | 4851 | 0.160 |
Why?
|
| Humans | 40 | 2023 | 744343 | 0.160 |
Why?
|
| Immune Evasion | 1 | 2021 | 360 | 0.160 |
Why?
|
| Receptors, Virus | 1 | 2021 | 648 | 0.150 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2021 | 4479 | 0.150 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2017 | 5442 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 9239 | 0.150 |
Why?
|
| Cranial Irradiation | 1 | 2020 | 401 | 0.150 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2016 | 197 | 0.130 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1038 | 0.130 |
Why?
|
| Saccharomyces cerevisiae | 3 | 2016 | 2752 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 3616 | 0.130 |
Why?
|
| Mutation | 5 | 2022 | 29786 | 0.130 |
Why?
|
| BK Virus | 1 | 2016 | 129 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 8428 | 0.130 |
Why?
|
| Saccharomyces cerevisiae Proteins | 2 | 2016 | 1888 | 0.120 |
Why?
|
| Computer Simulation | 2 | 2008 | 6196 | 0.120 |
Why?
|
| Thorax | 1 | 2018 | 547 | 0.120 |
Why?
|
| Neoplasm Staging | 6 | 2020 | 11031 | 0.120 |
Why?
|
| Radiotherapy, Conformal | 1 | 2018 | 548 | 0.120 |
Why?
|
| Spodoptera | 1 | 2014 | 153 | 0.120 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2015 | 134 | 0.120 |
Why?
|
| Polyomavirus Infections | 1 | 2016 | 197 | 0.120 |
Why?
|
| Treatment Outcome | 11 | 2020 | 63114 | 0.120 |
Why?
|
| Ion Channels | 2 | 2009 | 1056 | 0.120 |
Why?
|
| Antigens, Neoplasm | 1 | 2021 | 1988 | 0.110 |
Why?
|
| Tumor Burden | 1 | 2019 | 1915 | 0.110 |
Why?
|
| Tumor Virus Infections | 1 | 2016 | 452 | 0.110 |
Why?
|
| ROC Curve | 1 | 2021 | 3527 | 0.110 |
Why?
|
| Sex Distribution | 1 | 2018 | 2297 | 0.110 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 3586 | 0.110 |
Why?
|
| Opportunistic Infections | 1 | 2016 | 389 | 0.110 |
Why?
|
| Allosteric Regulation | 1 | 2014 | 408 | 0.110 |
Why?
|
| Capsid Proteins | 1 | 2016 | 479 | 0.110 |
Why?
|
| Transplantation, Homologous | 3 | 2017 | 4776 | 0.110 |
Why?
|
| Male | 20 | 2020 | 350118 | 0.110 |
Why?
|
| Hemolysin Proteins | 2 | 2009 | 113 | 0.100 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2016 | 713 | 0.100 |
Why?
|
| Neoadjuvant Therapy | 1 | 2022 | 2728 | 0.100 |
Why?
|
| Propensity Score | 1 | 2018 | 1781 | 0.100 |
Why?
|
| Angiopoietins | 1 | 2011 | 80 | 0.090 |
Why?
|
| Metaphase | 1 | 2010 | 151 | 0.090 |
Why?
|
| Transcription Factors | 3 | 2016 | 12208 | 0.090 |
Why?
|
| Dendritic Cells | 1 | 2021 | 2725 | 0.090 |
Why?
|
| Aged | 14 | 2020 | 163280 | 0.090 |
Why?
|
| SEER Program | 3 | 2020 | 1508 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2021 | 3474 | 0.090 |
Why?
|
| World Health Organization | 1 | 2015 | 1318 | 0.090 |
Why?
|
| DNA, Viral | 1 | 2016 | 2225 | 0.090 |
Why?
|
| Brain Neoplasms | 3 | 2020 | 8863 | 0.080 |
Why?
|
| Middle Aged | 15 | 2020 | 213383 | 0.080 |
Why?
|
| Retrospective Studies | 11 | 2019 | 77449 | 0.080 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2014 | 736 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 3597 | 0.080 |
Why?
|
| Head and Neck Neoplasms | 2 | 2020 | 2734 | 0.080 |
Why?
|
| Patient Care Team | 1 | 2020 | 2531 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2022 | 7913 | 0.080 |
Why?
|
| Female | 19 | 2021 | 380194 | 0.080 |
Why?
|
| Computational Biology | 1 | 2021 | 3521 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2018 | 2455 | 0.080 |
Why?
|
| Karyotyping | 1 | 2010 | 1243 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 2948 | 0.080 |
Why?
|
| Stem Cells | 1 | 2021 | 3567 | 0.080 |
Why?
|
| Potassium Channel Blockers | 1 | 2008 | 171 | 0.080 |
Why?
|
| Health Status Disparities | 1 | 2020 | 1797 | 0.080 |
Why?
|
| Porins | 1 | 2008 | 81 | 0.080 |
Why?
|
| Neurosurgical Procedures | 2 | 2017 | 2002 | 0.080 |
Why?
|
| Survival Rate | 2 | 2021 | 12788 | 0.080 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 1378 | 0.080 |
Why?
|
| Hippocampus | 1 | 2020 | 3675 | 0.080 |
Why?
|
| Solutions | 1 | 2008 | 426 | 0.070 |
Why?
|
| Cell Cycle Proteins | 1 | 2019 | 3462 | 0.070 |
Why?
|
| Graft vs Host Disease | 2 | 2017 | 2957 | 0.070 |
Why?
|
| Aneuploidy | 1 | 2010 | 530 | 0.070 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 3846 | 0.070 |
Why?
|
| DNA-Binding Proteins | 2 | 2016 | 9648 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2022 | 5172 | 0.070 |
Why?
|
| Prostate-Specific Antigen | 1 | 2016 | 2494 | 0.070 |
Why?
|
| Singapore | 2 | 2018 | 295 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2020 | 6538 | 0.070 |
Why?
|
| Bacterial Toxins | 2 | 2009 | 931 | 0.070 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 2529 | 0.070 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 12354 | 0.070 |
Why?
|
| Boronic Acids | 1 | 2010 | 965 | 0.070 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 1596 | 0.070 |
Why?
|
| Potassium Channels | 1 | 2008 | 563 | 0.070 |
Why?
|
| Risk Factors | 5 | 2020 | 72290 | 0.070 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2008 | 404 | 0.060 |
Why?
|
| Pancreas | 2 | 2023 | 1686 | 0.060 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2014 | 1352 | 0.060 |
Why?
|
| Pyrazines | 1 | 2010 | 1230 | 0.060 |
Why?
|
| Sex Factors | 1 | 2018 | 10397 | 0.060 |
Why?
|
| Graft Rejection | 1 | 2017 | 4397 | 0.060 |
Why?
|
| Aged, 80 and over | 6 | 2019 | 57776 | 0.060 |
Why?
|
| Nanotechnology | 1 | 2009 | 710 | 0.060 |
Why?
|
| Chemokine CXCL1 | 1 | 2023 | 101 | 0.060 |
Why?
|
| Darkness | 1 | 2023 | 167 | 0.060 |
Why?
|
| DNA | 2 | 2014 | 7301 | 0.060 |
Why?
|
| Incidence | 2 | 2018 | 20947 | 0.060 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2017 | 2208 | 0.050 |
Why?
|
| Chromatin | 1 | 2014 | 2934 | 0.050 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2009 | 828 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2019 | 2618 | 0.050 |
Why?
|
| Fluorescence Resonance Energy Transfer | 2 | 2016 | 401 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 13695 | 0.050 |
Why?
|
| Adult | 9 | 2019 | 214055 | 0.050 |
Why?
|
| Receptors, CCR6 | 1 | 2021 | 81 | 0.050 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 3507 | 0.050 |
Why?
|
| Escherichia coli Proteins | 1 | 2008 | 1050 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2020 | 1624 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2023 | 357 | 0.050 |
Why?
|
| Biology | 1 | 2023 | 294 | 0.050 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2011 | 1632 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2019 | 53288 | 0.040 |
Why?
|
| Actuarial Analysis | 1 | 2019 | 378 | 0.040 |
Why?
|
| Disease Progression | 3 | 2023 | 13284 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 11524 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2011 | 3386 | 0.040 |
Why?
|
| Oropharynx | 1 | 2018 | 127 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2018 | 40561 | 0.040 |
Why?
|
| Infant | 1 | 2019 | 35136 | 0.040 |
Why?
|
| Mitotic Index | 1 | 2017 | 172 | 0.040 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 39050 | 0.040 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2019 | 286 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2019 | 41006 | 0.040 |
Why?
|
| Standard of Care | 1 | 2020 | 564 | 0.030 |
Why?
|
| Cystitis | 1 | 2016 | 93 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2023 | 1692 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2019 | 10252 | 0.030 |
Why?
|
| Pancreatectomy | 1 | 2020 | 804 | 0.030 |
Why?
|
| Necrosis | 1 | 2019 | 1643 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2017 | 644 | 0.030 |
Why?
|
| Asia, Southeastern | 1 | 2014 | 111 | 0.030 |
Why?
|
| Animals | 5 | 2021 | 168757 | 0.030 |
Why?
|
| Peptides | 2 | 2021 | 4409 | 0.030 |
Why?
|
| Epitopes | 1 | 2021 | 2571 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2017 | 684 | 0.030 |
Why?
|
| Recurrence | 2 | 2017 | 8340 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2017 | 15295 | 0.030 |
Why?
|
| Models, Biological | 2 | 2008 | 9583 | 0.030 |
Why?
|
| Membrane Proteins | 2 | 2008 | 7880 | 0.030 |
Why?
|
| United States | 2 | 2020 | 69872 | 0.030 |
Why?
|
| Probability | 1 | 2019 | 2505 | 0.030 |
Why?
|
| Graft Survival | 2 | 2017 | 3737 | 0.030 |
Why?
|
| Skull Base Neoplasms | 1 | 2017 | 284 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 1838 | 0.030 |
Why?
|
| Adolescent | 5 | 2019 | 85781 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2019 | 2879 | 0.030 |
Why?
|
| Base Pairing | 1 | 2013 | 141 | 0.030 |
Why?
|
| Brain | 1 | 2019 | 26385 | 0.030 |
Why?
|
| Multiple Myeloma | 1 | 2010 | 5181 | 0.030 |
Why?
|
| DNA Repair | 1 | 2022 | 2046 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 1782 | 0.030 |
Why?
|
| Mice | 4 | 2021 | 81183 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2021 | 2540 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 3479 | 0.030 |
Why?
|
| Hydrolysis | 1 | 2013 | 682 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2015 | 492 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 15076 | 0.020 |
Why?
|
| Young Adult | 4 | 2019 | 56430 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 2183 | 0.020 |
Why?
|
| Social Class | 1 | 2020 | 1999 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2016 | 847 | 0.020 |
Why?
|
| Neutrophils | 1 | 2023 | 3719 | 0.020 |
Why?
|
| Remission Induction | 1 | 2015 | 2386 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2020 | 1859 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2021 | 13815 | 0.020 |
Why?
|
| Electrochemistry | 1 | 2009 | 145 | 0.020 |
Why?
|
| Vaccination | 1 | 2021 | 3278 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2017 | 2170 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2011 | 657 | 0.020 |
Why?
|
| Microchip Analytical Procedures | 1 | 2008 | 29 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2019 | 2616 | 0.020 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2013 | 635 | 0.020 |
Why?
|
| Cell-Free System | 1 | 2008 | 344 | 0.020 |
Why?
|
| Radiosurgery | 1 | 2017 | 1329 | 0.020 |
Why?
|
| Viral Load | 1 | 2016 | 3299 | 0.020 |
Why?
|
| Electrodes | 1 | 2009 | 619 | 0.020 |
Why?
|
| Algorithms | 1 | 2007 | 13881 | 0.020 |
Why?
|
| Membranes, Artificial | 1 | 2008 | 378 | 0.020 |
Why?
|
| Genomics | 1 | 2022 | 5720 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2019 | 23338 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 6171 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2013 | 2025 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 3086 | 0.020 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2011 | 496 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2010 | 2124 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2010 | 1420 | 0.020 |
Why?
|
| Fetal Blood | 1 | 2011 | 1318 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 2649 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2016 | 3461 | 0.010 |
Why?
|
| Phenotype | 1 | 2021 | 16365 | 0.010 |
Why?
|
| Inflammation | 1 | 2023 | 10638 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2011 | 1678 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 1375 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 4149 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2011 | 2263 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 2382 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2017 | 10481 | 0.010 |
Why?
|
| Time Factors | 2 | 2016 | 40075 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2011 | 4026 | 0.010 |
Why?
|
| Bone Marrow | 1 | 2010 | 2948 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 17446 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2011 | 19229 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2011 | 10180 | 0.010 |
Why?
|